170 related articles for article (PubMed ID: 17154520)
1. Improved therapeutic efficacy of doxorubicin through conjugation with a novel peptide drug delivery technology (Vectocell).
Meyer-Losic F; Quinonero J; Dubois V; Alluis B; Dechambre M; Michel M; Cailler F; Fernandez AM; Trouet A; Kearsey J
J Med Chem; 2006 Nov; 49(23):6908-16. PubMed ID: 17154520
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.
Liang JF; Yang VC
Bioorg Med Chem Lett; 2005 Nov; 15(22):5071-5. PubMed ID: 16168650
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives.
Bisi A; Meli M; Gobbi S; Rampa A; Tolomeo M; Dusonchet L
Bioorg Med Chem; 2008 Jul; 16(13):6474-82. PubMed ID: 18522868
[TBL] [Abstract][Full Text] [Related]
4. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts.
Pratesi G; De Cesare M; Caserini C; Perego P; Dal Bo L; Polizzi D; Supino R; Bigioni M; Manzini S; Iafrate E; Salvatore C; Casazza A; Arcamone F; Zunino F
Clin Cancer Res; 1998 Nov; 4(11):2833-9. PubMed ID: 9829750
[TBL] [Abstract][Full Text] [Related]
5. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4, 3-gh]isoquinolin-6(2H)-ones (9-aza-anthrapyrazoles).
Krapcho AP; Menta E; Oliva A; Di Domenico R; Fiocchi L; Maresch ME; Gallagher CE; Hacker MP; Beggiolin G; Giuliani FC; Pezzoni G; Spinelli S
J Med Chem; 1998 Dec; 41(27):5429-44. PubMed ID: 9876113
[TBL] [Abstract][Full Text] [Related]
8. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate.
Wang Y; Li L; Jiang W; Yang Z; Zhang Z
Bioorg Med Chem Lett; 2006 Jun; 16(11):2974-7. PubMed ID: 16563756
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and biological evaluation of doxorubicin-formaldehyde conjugates targeted to breast cancer cells.
Burke PJ; Koch TH
J Med Chem; 2004 Feb; 47(5):1193-206. PubMed ID: 14971899
[TBL] [Abstract][Full Text] [Related]
11. Antitumor agents 253. Design, synthesis, and antitumor evaluation of novel 9-substituted phenanthrene-based tylophorine derivatives as potential anticancer agents.
Wei L; Shi Q; Bastow KF; Brossi A; Morris-Natschke SL; Nakagawa-Goto K; Wu TS; Pan SL; Teng CM; Lee KH
J Med Chem; 2007 Jul; 50(15):3674-80. PubMed ID: 17585747
[TBL] [Abstract][Full Text] [Related]
12. Fatty acyl amide derivatives of doxorubicin: synthesis and in vitro anticancer activities.
Chhikara BS; St Jean N; Mandal D; Kumar A; Parang K
Eur J Med Chem; 2011 Jun; 46(6):2037-42. PubMed ID: 21420207
[TBL] [Abstract][Full Text] [Related]
13. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and cytotoxic evaluation of novel spirohydantoin derivatives of the dihydrothieno[2,3-b]naphtho-4,9-dione system.
Gomez-Monterrey I; Santelli G; Campiglia P; Califano D; Falasconi F; Pisano C; Vesci L; Lama T; Grieco P; Novellino E
J Med Chem; 2005 Feb; 48(4):1152-7. PubMed ID: 15715481
[TBL] [Abstract][Full Text] [Related]
15. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
16. Semisynthetic maytansine analogues for the targeted treatment of cancer.
Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV
J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799
[TBL] [Abstract][Full Text] [Related]
17. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery.
Du JZ; Du XJ; Mao CQ; Wang J
J Am Chem Soc; 2011 Nov; 133(44):17560-3. PubMed ID: 21985458
[TBL] [Abstract][Full Text] [Related]
18. Dipeptide-based highly potent doxorubicin antibody conjugates.
Jeffrey SC; Nguyen MT; Andreyka JB; Meyer DL; Doronina SO; Senter PD
Bioorg Med Chem Lett; 2006 Jan; 16(2):358-62. PubMed ID: 16275070
[TBL] [Abstract][Full Text] [Related]
19. Overcoming multidrug resistance in human carcinoma cells by an antisense oligodeoxynucleotide--doxorubicin conjugate in vitro and in vivo.
Ren Y; Wang Y; Zhang Y; Wei D
Mol Pharm; 2008; 5(4):579-87. PubMed ID: 18461970
[TBL] [Abstract][Full Text] [Related]
20. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
